Prelude Therapeutics Inc

PRLDSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1678660

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$7.0M	$7.0M	—	—	—
Research and Development Expense	$118.0M	$103.4M	$92.9M	$86.8M	$48.2M
Operating Expenses	$146.7M	$132.3M	$123.5M	$113.7M	$58.8M
Operating Income (Loss)	-$139.7M	-$132.3M	-$123.5M	-$113.7M	-$58.8M
Other Nonoperating Income (Expense)	$12.5M	$10.4M	$8.1M	$2.0M	$1.8M
Income Tax Expense (Benefit)	$0.00	—	—	—	—
Net Income (Loss) Attributable to Parent	-$127.2M	-$121.8M	-$115.4M	-$111.7M	-$56.9M
Earnings Per Share, Basic

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$175.5M	$277.7M	$220.5M	$305.1M	$223.6M
Assets, Current	$135.9M	$235.6M	$204.4M	$295.1M	$220.8M
Cash and Cash Equivalents, at Carrying Value	$12.5M	$25.3M	$30.6M	$31.8M	$218.3M
Liabilities	$44.1M	$40.6M	$25.1M	$19.2M	$11.4M
Liabilities, Current	$25.6M	$21.8M	$21.7M	$19.2M	$11.4M
Accounts Payable, Current	$7.7M	$4.6M	$6.8M	$7.8M	$3.9M
Stockholders' Equity Attributable to Parent	$237.1M	$195.4M	$285.9M	$212.2M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$102.9M	-$107.1M	-$83.7M	-$83.5M	-$46.2M
Net Cash Provided by (Used in) Investing Activities	$90.2M	-$34.6M	$81.7M	-$263.8M	-$621.0K
Net Cash Provided by (Used in) Financing Activities	-$120.0K	$136.4M	$815.0K	$164.9M	$246.2M
Payments to Acquire Property, Plant, and Equipment	$764.0K	$3.5M	$3.0M	$2.3M	$621.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)